In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption

We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody, mAb)-trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2(low) human pancreatic carcinoma xenografts. Here, we compared the 2mAbs therapy, the...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Larbouret, Christel, Gaborit, Nadège, Chardès, Thierry, Coelho, Mickaël, Campigna, Emmanuelle, Bascoul-Mollevi, Caroline, Mach, Jean-Pierre, Azria, David, Robert, Bruno, Pèlegrin, André
格式: Artigo
語言:Inglês
出版: Neoplasia Press Inc. 2012
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306257/
https://ncbi.nlm.nih.gov/pubmed/22431920
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍